Format

Send to

Choose Destination
Int J Hematol. 2017 Jun;105(6):711-719. doi: 10.1007/s12185-017-2243-z. Epub 2017 Apr 28.

CMML: Clinical and molecular aspects.

Author information

1
Hematology Department, Hopital Saint-Louis, Assistance Publique, Hopitaux de Paris, Paris Diderot University, 1, Avenue Claude Vellefaux, 75010, Paris, France. raphael.itzykson@aphp.fr.
2
INSERM U944, Institut Universitaire d'Hématologie, Paris, France. raphael.itzykson@aphp.fr.
3
INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France.
4
Hematology Departement, Gustave Roussy Cancer Center, Villejuif, France.

Abstract

Chronic Myelomonocytic Leukemia is a chronic myeloid neoplasm occurring mostly in the elderly with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) characterized by chronic monocytosis. Recent progresses in the molecular and cellular pathogenesis of CMML have stirred a renewed interest in this clinically heterogeneous disorder. Here, we review the recent progresses in the biology of CMML and how it affects its current and future clinical management.

KEYWORDS:

Chronic myelomonocytic leukemia; Myelodysplastic; Myeloproliferative

PMID:
28455647
DOI:
10.1007/s12185-017-2243-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center